Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Recruiting

Phase 2

AvapritinibAvapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04771520

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8

Locally Advanced Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avapritinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-02-17.